HGH Fragment 176-191 is a synthetic peptide corresponding to the C-terminal portion (amino acids 176-191) of human growth hormone. This 16-amino acid fragment was identified as the region of GH responsible for its lipolytic (fat-burning) activity. It was studied for its ability to promote fat loss without the diabetogenic, growth-promoting, or IGF-1-stimulating effects of full-length GH. A stabilized analog, AOD-9604, reached Phase III clinical trials but failed to demonstrate sufficient efficacy for obesity. WADA bans this peptide.
3 vendors tracked by PeptideAtlas list HGH Fragment 176-191, priced from $25.49 to $80.00. The lowest price per milligram is $8.00/mg at Pacific Peptide (10mg).
Category: Growth Hormone Fragment. Evidence rating: D (animal/preclinical only).
Clinical status: Preclinical. The stabilized analog AOD-9604 completed Phase III for obesity but failed primary efficacy endpoints.
HGH Fragment 176-191 mimics the lipolytic action of the C-terminal loop of growth hormone. It stimulates lipolysis (fat breakdown) and inhibits lipogenesis (fat formation) in adipose tissue, reportedly through a mechanism independent of the GH receptor and without activating IGF-1 production.…
Safety considerations: Limited human safety data (mainly from AOD-9604 trials); AOD-9604 clinical trials reported no significant safety concerns at studied doses; No effect on blood glucose or insulin in available data.
Reviewed by the PeptideAtlas Editorial Team.
| Amino-acid sequence | Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe (16 amino acids) |
|---|---|
| Molecular weight | ~1817.1 g/mol |
| Production method | synthetic |
| Anti-doping status | Prohibited in sport (WADA) |
| US regulatory status | Not FDA-approved. Research chemical only. WADA-banned. |
| Vendor | Size | Price | Price per mg |
|---|---|---|---|
| Pacific Peptide | 10mg | $80.00 | $8.00/mg |
| BioTech Peptides | 5mg | $47.00 | $9.40/mg |
| Wholesale Peptide | 2mg | $25.49 | $12.74/mg |
HGH Fragment 176-191 is the native C-terminal sequence (amino acids 176-191) of human growth hormone. AOD-9604 is a stabilized, modified version of this fragment with improved stability. AOD-9604 advanced further in clinical development but ultimately failed Phase III trials for obesity.
Animal and in vitro data show genuine lipolytic activity. However, the stabilized analog AOD-9604 failed to demonstrate significant weight loss in a large Phase III clinical trial. This suggests that the fat-loss effects seen in preclinical models may not translate to clinically meaningful results in humans.
No. Fragment 176-191 does not activate the GH receptor in the same way as full-length GH and does not stimulate IGF-1 production. Its mechanism is limited to direct effects on adipose tissue.
Vendors stocking it: BioTech Peptides, Zztai Peptide, Mia Peptide, Ultima Pharmaceuticals, Pacific Peptide, Wholesale Peptide, NCRP Canada, Tide Labs, Disguised Alpha, Toronto Peptides, Montreal Peptides, Pure Peptides UK, DAHAN Peptide.
Coverage on this site: Alcohol Wipes: Key to Sterile Peptide Preparation.